The purpose of this study is to evaluate the efficacy and safety of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP for the treatment of the GCB subtype of DLBCL.

Have you been diagnosed with Waldenstrom Macroglobulinemia (WM) cancer? If so, you may be able to take part in a research study to determine if epcoritamab can be used to treat patients with previously treated WM.

The main purpose of this study is to test the safety of a gene therapy. Scientists have created a gene in the laboratory that could be transferred to the cells in the body. This gene carries information to tell the cells how to make an antibody (protein). The antibody (protein) is very similar to an antibody (protein) called blinatumomab. Blinatumomab is an FDA-approved treatment for relapsed or refractory B-cell ALL. This gene therapy is not approved by the FDA, therefore is it experimental. This study tests different doses of the gene therapy to see which dose is safer in people since it has not been tested in people yet.

In this study, we are looking at a medicine called ZE50-0134 that might help treat people with relapsed and refractory CLL, SLL, or certain low-grade lymphomas. We want to see if taking different amounts of this medicine in capsule form is safe for patients.

Have you been diagnosed with CLL or other forms of indolent lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of this study is To investigate the feasibility of the referral and engagement process in fatigue mitigation intervention for cancer-related fatigue among adults with CLL or other forms of indolent lymphoma.

Do you have recurring Chronic Lymphocytic Leukemia? If so, you may be able to take part in a study on two medicines to treat patients whose chronic lymphocytic leukemia has come back. We will also check if this treatment is safe for treatment.

Do you have T-cell Lymphoma? Is your disease relapsed or refractory and CD5 positive? If so, you may be able to participate in this gene therapy research study to learn more about using your own modified immune cells as possible treatment.

Do you have relapsed peripheral T-cell lymphoma (PTCL)? Has your cancer not gotten better with other treatments, or were those treatments stopped because of bad side effects? If so, you might be able to join a study to see if a new drug called Soquelitinib (also known as CPI-818) can treat PTCL better.

Have you been diagnosed with cancer. If so, you may be able to take part in a research study looking to improve cancer care for patients whose treatment outcomes have led to challenges in their quality of life.

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States